INTRODUCTION: This scoping review mapped common specifications, standards and overlapping regulations for high-risk and innovative medical devices (MDs) and in vitro diagnostic medical devices (IVDs) in the European Union (EU), United States (US) and China to clarify compliance pathways and support regulatory harmonization. METHODS: Following Joanna Briggs Institute (JBI) and PRISMA-ScR guidance, we searched PubMed, Scopus/Embase and Web of Science for studies on MD/IVD regulation, standards and common specifications in the aforementioned territories. Eligible records were screened in two stages, with data extracted using a structured form and synthesized narratively by regulatory pathway, standards, common specifications, and guidelines. RESULTS: Of 3093 records identified, 2262 were screened and 275 met inclusion criteria. Across jurisdictions, regulation converges on risk-based classification, lifecycle clinical evidence, quality management and post-market surveillance. Differences persist in evidentiary thresholds, implementation timelines, regulator/notified-body capacity and requirements for software, Artificial Intelligence (AI), laboratory-developed tests and local testing, which are particularly challenging for Small and Medium Enterprises (SMEs). CONCLUSIONS: Regulatory frameworks in these territories are aligned in principle but variably specified and implemented, creating complexity for global market access. Clearer guidance on common specifications, explicit expectations for emerging technologies and harmonized post-market evidence requirements may reduce duplication while maintaining patient safety.
Teixeira et al. (Tue,) studied this question.